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Abstract: The removal of diclofenac sodium ophthalmic solution as a viable pharmaceutical 
entity in September 1999 from the US market spurred considerable interest in the general safety 
and effectiveness of topical ophthalmic NSAIDs for treatment of anterior segment inﬂ  amma-
tion. In late 1999 the use of topical ocular NSAIDs declined in the US as a result of incidents 
involving corneal melts and toxicity surrounding use of generic diclofenac. However, since the 
removal of diclofenac sodium ophthalmic solution from the marketplace, ophthalmic NSAIDs 
have regained use as viable pharmacotherapeutic entities. Moreover, several new ophthalmic 
NSAID products have recently been introduced for commercial use in the US including the 
novel chemical entity nepafenac. The purpose of this report is to revisit the use of topical oph-
thalmic NSAIDs for the treatment of surgically induced anterior segment inﬂ  ammation with a 
particular focus on nepafenac. Nepafenac is unique among ophthalmic NSAIDs in that it is a 
prodrug deaminated to amfenac, a highly effective non-selective cyclooxygenase inhibitor. In 
the case of topical ophthalmic NSAIDs, practitioners should carefully weigh the cost-beneﬁ  t of 
implementing “highly potent” new drug products because perturbations in pharmacodynamic 
response due to the inherent novelty in terms of chemical designs may outweigh the demonstrated 
replicative pharmacologic action of all topical ophthalmic NSAIDs.
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Introduction
Prior to use of ophthalmic non-steroidal anti-inﬂ  ammatory suspensions, topical ophthal-
mic steroids were the mainstay treatment of post-operative, surgically induced ocular 
inﬂ  ammation. Although considered very effective, the use of topical corticosteroids 
is limited by well known side effects which in some serious cases can precipitate 
vision loss, and limits such therapy to short, intermittent use. Topical non-steroidal 
anti-inﬂ  ammatory drugs (NSAIDs) are notable for a deﬁ  nitive lack of corticosteroid-
deﬁ  ned toxicity and have secured an important role, albeit in some cases an undeﬁ  ned 
role, in the treatment of ocular inﬂ  ammatory disease.
Acute inﬂ  ammation can be the result of exogenous injury either iatrogenic or due 
to accidents as well as of endogenous origin such as occurs in autoimmune disease. 
The use of the term inﬂ  ammation in the context of the present report, however, will be 
limited to that of inﬂ  ammation due to exogenous origin secondary to post-operative 
ophthalmic surgery related to the production of various eicosanoids. Eicosanoids are 
deﬁ  ned as prostaglandins, leukotrienes, and other compounds that are products of the 
action of phospholipase A2 on the cellular phospholipid membrane and are, in general, 
derived from the production of arachidonic acid (Figure 1).
It has been shown that cyclooxygenase enzymes play a key role in maintain-
ing cellular integrity and preventing apoptosis in eukaryotes (Xiaojun et al 1995). 
The eicosanoid products of cyclooxygenase play a vital role in cellular homeostasis 
such as modulation of platelet function as well as renal regulation of salt and water Clinical Ophthalmology 2008:2(2) 356
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balance (Morrow and Roberts 2002). However, up-regula-
tion of the cyclooxygenase enzyme system has been docu-
mented secondary to injury and results in overproduction 
of eicosanoids normally required for cellular homeostasis. 
An overabundance of eicosanoids converts these otherwise 
essential compounds to rampant mediators of inﬂ  ammation. 
Unlike corticosteroids, which exhibit a broader effect on 
suppression of inﬂ  ammation through inhibition of phos-
pholipase A2 and through various cellular effects, NSAIDs 
act primarily through the inhibition of the cyclooxygenase 
(COX) enzyme isoforms. Interestingly, NSAIDs also have 
been demonstrated to exert anti-inﬂ  ammatory activity by 
mechanisms unrelated to COX inhibition through suppression 
of polymorphonuclear (PMN) locomotion and chemotaxis as 
well as by decreasing expression of inﬂ  ammatory cytokines 
and mast cell degranulation (Periann et al 1985; Leonardi 
et al 2000). There is also evidence that NSAIDs exert activity 
as free radical scavengers, a ﬁ  nding that may also contribute 
to lessen the inﬂ  ammatory response (Flach 1992).
It is now well established that two forms of COX exist. 
A constitutive isoform, COX1, is equally expressed upon the 
endoplasmic reticulum of all cells including platelets, cel-
lular elements of the small and large bowel mucosa, vascular 
endothelium renal medullary collecting ducts, interstitium, 
pulmonary and hepatic sites, as well as the spleen (Needleman 
and Isakson 1997). COX2 is the induced isoform formed in 
part by various cytokines and various inﬂ  ammatory mediators 
secondary to inﬂ  ammation (Crofford 1997). It is noteworthy 
that in the mammalian cornea, arachadonate may also be 
routed into a distinct metabolic pathway involving cyto-
chrome P 450 (CYP) enzyme systems in addition to COX 
and lipoxygenase pathways (Figure 2) (Schwartzman and 
Abraham 1990). In the corneal epithelium, arachidonate is 
metabolized by CYP systems that results in the biologically 
active species, 12(R) – hydroxyl – 5,8,10,14 eicosatetraenoic 
acid [12(R) – HETE] and 12(R) – hydroxyl -5,8,14-eicosatet-
raenoic acid [12(R) – HETrE] (Schwartzman and Abraham 
1990; Mieyal et al 2000). 12(R) – HETE is a potent inhibitor 
of Na+ - K+ ATPase as well as mediating PMN aggregation 
(Masferrer et al 1990; Mieyal et al 2000, 2001). 12(R) – 
HETErE also plays a role in inﬂ  ammation through mediation 
of conjunctival vasodilatation, and increasing permeability of 
the blood – aqueous barrier in addition to acting as an aggregate 
for PMN leukocytes (Davis et al 1990). Descriptive clinical 
ramiﬁ  cations of corneal inﬂ  ammation derived from activity of 
the CYP systems remain to be further elucidated.
Classiﬁ  cation of NSAIDs
Classiﬁ  cation of NSAIDs is often noted by their chemical 
constituents as well as their activity on COX1 and COX2, 
respectively. NSAIDs available commercially for topical 
ophthalmic use are considered organic acids, with the excep-
tion of nepafenac, which is a benzoylbenzeneacetamide 
prodrug metabolized in vivo to its corresponding acid. Cur-
rently available ophthalmic NSAID products in the US are 
considered phenylacetic or phenylalkanoic acids, including 
nepafenac which is a substituted phenylacetic acid. Other 
chemical entities considered as NSAIDs such as salicylates, 
Figure 1 General pathways of arachidonic acid metabolism.
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fenamates and pyrazolone derivatives are considered too 
toxic for use in the eye (Flach 1992). An outline of currently 
used topical ophthalmic NSAIDs, their approved use in the 
US, as well as their chemical structure and class are outlined 
in Table 1 and Figure 3, respectively.
Commercially available topical ophthalmic NSAIDs are 
in large part solutions, with the exception of nepafenac which 
is a suspension, and vary based on the inclusion of inactive 
components utilized in embodiments as preservatives, sur-
factants, tonicity agents, viscosity enhancers, and buffers. 
As multi-use ophthalmic preparations require the presence 
of a preservative, the inclusion of anti-microbial compounds 
in the ophthalmic solution is imperative in the prevention of 
contamination of the solution.
As COX inhibition is the major outcome parameter of 
anti-inﬂ  ammatory potential of NSAID application in vitro, 
the comparative effect of topical ophthalmic NSAIDs on 
COX1 and COX2 activities is also of interest, at least from an 
experimental standpoint. Classical NSAIDs with arylacetic 
acid structure are known to be potent inhibitors of the COX 
isoforms that promote a time-dependent inactivation of 
enzyme activity with increasing duration of drug exposure 
(Flach 1990). The inhibitory action against COX is markedly 
reduced, however, when arylacetic NSAIDs are esteriﬁ  ed. 
Indeed, as an amide analog, nepafenac demonstrates weak 
COX activity; however its free acid, amfenac, is a potent 
inhibitor of both COX1 and COX2 isoforms (Gamache et al 
2000). Topical NSAIDs differ based on their afﬁ  nity for the 
COX enzyme and activity in terms of enzyme inhibition. 
However, studies examining relative inhibitory COX activ-
ity of NSAIDs often utilize differing protocols and enzyme 
sources; therefore the comparative assessment of NSAID 
IC50 is not directly correlative.
It is important to exert caution when interpreting IC50 
values for various NSAIDs in terms of clinical effectiveness. 
For example, COX activity can vary based solely on the 
species used to derive enzyme (Warner 2001). Furthermore, 
one must differentiate between in vitro testing at the cellular 
level or use of isolated enzymes. If one uses cells, a further 
caveat includes the inclusion of cofactors, for example glu-
tathione or epinephrine that may affect enzyme rate (Warner 
2001). Moreover, incubation times may vary, affecting rate 
of enzyme activity. Finally, the choice of an index of activ-
ity, eg, prostaglandin E2, thromboxane, or other markers of 
COX enzyme activity may affect determination of NSAID 
inhibitory potential (Warner 2001).
Despite the intuitive impulse to equate clinical effective-
ness with NSAID potency, the non-parallel nature of inhibitor 
curves makes interpretation of IC50 levels clinically quite 
difﬁ  cult (Warner 2001). It noteworthy to emphasize that 
potency does not equate to efﬁ  cacy. Indeed potency is rela-
tively unimportant in the overall scheme of pharmacotherapy 
as long as the chemical entity in and of itself is devoid of 
marked dose-dependent toxicity as is the generally the 
case with ophthalmic application of NSAIDs (Nies 2001; 
Lekhanont et al 2007).
Figure 2 Pathways of arachadonate metabolism in the cornea. Reproduced with permission from Mieyal PA, Bonazzi A, Jiang H, et al 2000. The effect of hypoxia on endogenous 
corneal epithelial eicosanoids. Invest Ophthalmol Vis Sci, 41:2170–6. Copyright © 2000.   Association for Research in Vision and Ophthalmology.
Abbreviations: CYP450, cytochrome P450; 12-HETE, 12(R)-hydroxy-5, 8, 11, 14-eicosatetraenoic acid; 12(R)-HETrE, 12(R)-hydroxy-5, 8, 14-eicosatrienoic acid; PG, prostaglandin.
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Although all topical ophthalmic NSAIDs may be con-
sidered non-selective COX inhibitors, the relative ratio 
of COX1:COX2 inhibitory potential of each agent differs 
markedly. In terms of COX isoforms demonstrable in corneal 
epithelium subsequent to experimentally induced hypoxia-
derived inﬂ  ammation, COX2 protein, but not COX1, was 
found to dramatically increase rabbit corneal epithelium 
after cellular hypoxia (Schwartzman et al 2003). COX2 
protein has also been noted in the canine model of corneal 
inflammation as well (Schwartzman et al 2003; Sellars 
et al 2004). However, corneal inﬂ  ammation as result of 
hypoxia was found unrelated to the presence of the inﬂ  am-
matory mediator PGE2 in the rabbit model. The lack of a 
concomitant increase in prostanoid PGE2 despite elevation 
in COX2 protein thereby suggests an alternative source of 
hypoxia-deﬁ  ned corneal inﬂ  ammation aside from prostanoid 
compounds.
Of further interest, several studies have demonstrated 
that prostaglandins may in some cases have frank anti-
inﬂ  ammatory properties and thus may be beneﬁ  cial in combat-
ing ocular inﬂ  ammation. For example, PGE2 has been shown 
to inhibit LTB4-induced PMN inﬁ  ltration into the anterior 
chamber of the rabbit eye (Kulkarni 1991). Furthermore, in 
the rabbit hypoxia model of corneal injury, inhibition of COX 
by indomethacin or aspirin resulted in potentiation of the 
release of PMNs into the tear ﬁ  lm (Srinivasan and Kulkarni 
1989). Although the role of prostaglandins in beneﬁ  ting 
human corneal inﬂ  ammation has not been tested, it is widely 
known that in general topical ophthalmic NSAIDs are only 
partially effective in reducing corneal inﬂ  ammation in the 
human. NSAIDs may also potentiate peroximase proliferator-
activated receptors with subsequent induction of CYP4B1 
activity and production of the pro-inﬂ  ammatory compounds 
12-HETE and 12-HETrE. If such is the case, topical NSAIDs 
may not only be ineffective in treating corneal inﬂ  ammation 
in the human eye, but actually contribute to the inﬂ  ammatory 
response. These ﬁ  ndings back the general notion that topical 
NSAIDs are in general inferior to corticosteroids in treat-
ment of ocular surface inﬂ  ammation secondary to hypoxia 
(Srinivasan and Kulkarni 1989).
Table 1 Topical ophthalmic NSAID products approved for use in the US
Generic/marketed drug name (approved 
for use in the US)
FDA-approved indications Manufacturer recommended dosage
Diclofenac sodium ophthalmic solution 
0.1% (Voltaren®)
Post-operative inﬂ  ammation after cataract 
extraction
Cataract surgery: 1 drop to the affected eye, 
4 times daily beginning 24 hours after cataract 
surgery and continuing throughout the ﬁ  rst 
2 weeks of the post-operative period.
Post-operative pain and photophobia
following corneal refractive surgery
Corneal refractive surgery: 1 or 2 drops should 
be applied to the operative eye within the hour 
prior to corneal refractive surgery. Within 
15 min after surgery, 1 or 2 drops should be 
applied to the operative eye and continued 
4 times daily for up to 3 days.
Flurbiprofen ophthalmic solution 0.03% 
(Ocufen® – also available as a generic product 
in the US)
Inhibition of intra-operative miosis during 
cataract surgery
A total of 4 drops should be administered by 
instilling 1 drop approximately every 1/2 hour 
beginning 2 hours before cataract surgery.
Ketorolac tromethamine 0.5% ophthalmic 
solution (Acular®)
Seasonal allergic conjunctivitis One drop 4 times a day as needed
Post-op inﬂ  ammation after cataract
extraction
One drop 4 times a day beginning 1 day post-
operatively for 14 days
Ketorolac tromethamine 0.4% ophthalmic 
solution (Acular LS®)
Reduction of ocular pain and burning/stinging, 
after corneal refractive surgery
One drop 4 times a day in the operated eye as 
needed for pain and burning/stinging for up to 
4 days after corneal refractive surgery
Ketorolac tromethamine 0.5% ophthalmic 
solution (Acular PF®)
Reduction of ocular pain and photophobia
after incisional refractive surgery
One drop 4 times a day in the operated eye 
as needed for pain and photophobia for up to 
3 days after incisional refractive surgery.
Bromfenac ophthalmic solution 0.09% 
(XibromTM)
Post-op pain and Inﬂ  ammation after cataract 
extraction
One drop twice daily beginning 1 day post-
operatively x 14 days
Nepafenac ophthalmic suspension 0.1% 
(Nevanac®)
Post-operative pain and inﬂ  ammation after 
cataract extraction
One drop 3 times daily beginning 1 day pre-
operatively, continued on day of surgery then 
14 days post-operatively.Clinical Ophthalmology 2008:2(2) 359
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Figure 3 Chemical structures and names of topical ophthalmic NSAID products approved for use in the US.
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Nepafenac as an amide prodrug that requires hydrolysis to 
the more active amfenac entity, as noted in Figure 4.
Nepafenac as a parent compound exhibits weak intrinsic 
COX inhibitory activity (COX1 inhibitory activity IC50 
64.3 μM) (Hargrave et al 2002); however, it readily penetrates 
the rabbit cornea and distributes in all ocular tissues includ-
ing aqueous humor, iris, ciliary body, retina, and choroid 
(Gamache et al 2000). Amfenac is an arylacetic acid derivative 
(2-amino-3-benzoylbenzene acetic acid), which exhibits potent 
antipyretic and analgesic properties. Amfenac is currently 
marketed in Japan as a systemic formulation for treatment of 
rheumatoid arthritis and for pain and/or inﬂ  ammation after 
surgery (Fenazox®) (Needleman and Isakson 1997; Gamache 
et al 2000). A series of structural analogs of amfenac have been 
prepared to enhance the compound’s therapeutic index (Walsh 
et al 1990; Ruiz et al 1993). Interestingly, oral use of nepaf-
enac, the amide analog of 2-amino-3-benzoylbenzeneacetic 
acid, exhibited potent ant-inﬂ  ammatory activity but greatly 
reduced intestinal toxicity (Walsh et al 1990).
Studies examining the in vitro comparative pharmacody-
namic properties of nepafenac, amfenac, ketorolac, or brom-
fenac on COX activity demonstrated that ketorolac displays 
the greatest COX1 inhibitory activity while amfenac showed 
the greatest COX2 inhibitory potential (Walters et al 2007). 
Additional studies using PGE2 as a surrogate marker of 
COX activity have noted that ketorolac demonstrated greater 
effect in lowering aqueous levels of PGE2 levels compared 
to nepafenac (Bucci et al 2007). It should also be noted that 
nepafenac, as well as other topical ophthalmic NSAIDs, do not 
demonstrate activity on the 12(R) – HETE and 12(R) – HETrE 
inﬂ  ammatory mediators generated within the cornea by the 
action of CYP450 enzymes on arachidonic acid.
Topical ophthalmic nepafenac targets the anterior segment 
of the eye, intraocular and vascularized tissues. Following 
topical application the onset of nepafenac activity is around 
15 minutes and duration of action is greater than 8 hours 
(Stewart et al 2005) after topical administration (Nevanac®). 
Small quantiﬁ  able plasma concentrations of nepafenac and 
amfenac have been observed in subjects 2–3 hours after 
topical administration. After ocular administration the mean-
steady state Cmax of nepafenac and amfenac in serum were 
0.310 ± 0.014 ng/mL and 0.422 ± 0.121 ng/mL, respectively 
(Gamache et al 2000; Nevanac®). After oral administration 
nepafenac in rats was eliminated in urine (57%) and by the 
fecal route (40%) over a 7-day period (Bucci et al 2007). 
Nepafenac in the US was approved by the FDA (Food and 
Drug Administration) on August 19, 2005 as a priority drug 
approval (Lane 2006). Nepafenac is currently approved in the 
US only for treatment of pain and inﬂ  ammation associated 
with cataract surgery (Nevanac®). It has been studied for the 
relief of pain and photophobia associated with photorefractive 
surgery and retinal edema secondary to diabetic retinopathy 
but is currently not approved for these indications in the US 
(Colin and Paquette 2006).
Pharmacometrics of topically 
applied ophthalmic NSAIDs
Drug formulation is an important factor affecting drug 
absorption and takes into consideration the pH of the drug, 
preservatives, and vehicle type. The corneal absorption of a 
drug depends on its lipid solubility and inversely on its polar-
ity or degree of ionization. An important factor in the design 
of drugs for topical ophthalmic use that are commonly weak 
acids or bases involves the degree of penetration of a drug 
through the corneal epithelium. The more drug in its unionized 
form, the more likely it is to be lipid soluble and transferred 
by passive diffusion across the epithelial membrane. The pH 
of normal tears, which acts as a buffering system for many 
substances, varies between 6.5 and 7.6. Altering the pH 
solution of a slightly basic drug, for example from 6.2 to 7.5, 
Figure 4 Deamination of nepafenac to the active compound amfenac.
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renders a drug to a more unionized state and therefore more 
lipid soluble, which therefore increases corneal penetration 
and, notably, systemic absorption as well. Hence ophthalmic 
nepafenac being a base and maintained as an ophthalmic solu-
tion at pH 7.4 would exist more as a unionized drug and is 
therefore absorbed readily across the cornea at higher levels of 
tear pH. The marked advantage of using prodrugs to enhance 
corneal absorption of ophthalmic drugs has been demonstrated 
using isolated rabbit corneal tissue (Ke et al 2000). In a rabbit 
model, corneal permeability of nepafenac was demonstrated 
by a permeability coefﬁ  cient that was approximately 4, 19, and 
28 times greater than diclofenac, bromfenac, and ketorolac 
respectively (Ke et al 2000; Linstrom and Kim 2006). How-
ever, it should be pointed out that signiﬁ  cant differences exist 
between rabbit and human cornea both anatomically and in 
terms of pharmacokinetics of drug absorption (Owen et al 
2007). In general, penetration of drugs applied to the rabbit 
cornea far exceeds that seen in the human due to the relative 
thinness of the rabbit cornea (Owen et al 2007).
It is also notable that bioactivation of nepafenac into the 
active amfenac entity is negligible in the cornea (Ke et al 
2000). However, as noted previously nepafenac does appear 
to penetrate the rabbit cornea in amounts relatively higher 
than other NSAIDs, but once again a caveat must be noted 
concerning differences between the rabbit and human cornea. 
The tissue that appears to demonstrate the greatest hydrolytic 
activity for the nepafenac molecule has been shown in the 
rabbit to be the retina/choroid followed by the iris/ciliary 
body (Ke et al 2000). Bioactivation of nepafenac may also 
occur in aqueous humor presumably by aqueous hydrolytic 
enzymes. However, it is known that enzyme-protein concen-
tration in the human aqueous is negligible with albumin being 
the largest contributor of aqueous protein concentration. 
Enzyme activity is also poorly discernable in the aqueous 
with exception of plasminogen and plasminogen activator 
(Blakemore 1995).
As an amide, nepafenac (benzoylbenzeneacetamide) may 
be considered chemically analogous to N-methylacetamide 
and may undergo similar water hydrolysis once reaching the 
aqueous humor (Zahn 2004). It is quite possible however that 
metabolism of nepafenac in the aqueous occurs by amide 
hydrolysis induced by water. At neutral pH, nucleophilic 
attack by OH− is thought to be the rate limiting step of amide 
hydrolysis. The mechanism of water assisted hydrolysis has 
been investigated with use of N-methylacetamide using Car-
Parrinello molecular dynamic (CPMD) simulation, which 
suggests a proton transfer and attack of the amide by the 
hydroxyl ion (Zahn 2004).
In vivo study in humans has shown that when applied 
topically to the cornea, nepafenac demonstrates both a faster 
time to Cmax as well as a higher aqueous humor concentration 
than either bromfenac or ketorolac (Walters et al 2007). The 
mean area under the time-concentration curve of aqueous 
drug concentration was found to be signiﬁ  cantly higher for 
nepafenac than amfenac, ketorolac, or bromfenac (Walters 
et al 2007). However, it should be noted that the mean area 
under the curve for aqueous amfenac was found comparable 
to that of ketorolac (180.7 vs 176.9 ng × h/mL, respectively) 
(Walters et al 2007). In contrast, additional studies have 
noted that levels of aqueous ketorolac following topical 
ophthalmic administration in humans far exceeds that of 
amfenac or nepafenac following 2 days of 4-times-a-day 
drug administration (Bucci et al 2007). This ﬁ  nding is curious 
in view of the marked penetration potential of the prodrug 
nepafenac entity.
It should be noted that benzalkonium chloride and other 
cationic surfactants increase ocular absorption of drugs by 
increasing corneal permeability by compromise of corneal 
integrity (Forrester et al 2002). Indeed alternative ophthal-
mic NSAIDs such as ketorolac, ﬂ  urbiprofen, and bromfenac 
include benzalkonium chloride as a preservative, which may 
contribute to corneal permeability variances seen among 
these products.
Efﬁ  cacy of nepafenac in 
post-operative cataract
surgery-related inﬂ  ammation
Cataract surgery is an invasive procedure that requires inci-
sion and cutting of ocular tissue as well as considerable 
intraocular tissue manipulation. Iatrogenic injury to the eye 
leads to disruption of the blood aqueous barrier with cel-
lular inﬁ  ltration leading to intraocular inﬂ  ammation. Fibrin 
and protein accumulation in the anterior chamber may 
lead to complications of intraocular inﬂ  ammation such as 
increased intraocular pressure as well as corneal endothelial 
precipitates. Adhesions of the iris to the angle and/or lens 
implant as well as opaciﬁ  cation of posterior capsule may 
also be seen. Cellular debris on the lens implant and poste-
rior capsule may also lead to poor visual recovery. In severe 
cases post-operative inﬂ  ammation of the anterior segment 
secondary to surgical trauma may result in frank visual loss 
(Jampol et al 1994). Interestingly, topical NSAID treatment 
appears more effective than topical steroids in re-establishing 
the blood – aqueous barrier as quantitatively measured 
with anterior ocular ﬂ  urophotometry (Jampol et al 1994). Clinical Ophthalmology 2008:2(2) 362
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Additional uses of NSAIDS in regard to cataract surgery 
include prevention of surgically induced miosis that may 
hamper surgical outcome and treatment of complicating 
cystoid macular edema after lens removal. There is evidence 
that prophylactic use of NSAIDs prior to cataract surgery 
may in fact lessen post-operative inﬂ  ammation avoiding 
intraocular pressure-related complications incurred with 
frequent administration of high dose corticosteroids post-
operatively (Jampol et al 1994).
A total of 5 unpublished studies in humans have examined 
the use of nepafenac after cataract surgery (Nevanac®; Lane 
2006; National PBM drug monograph 2006). These studies 
included 1 pivotal trial (C-03-32), 1 efﬁ  cacy and safety study 
(C-02-53), 2 dose response studies (C-95-93 and C-97-30), as 
well as 1 trial comparing safety and tolerability of nepafenac 
with diclofenac C-95-91. In studies C-02-53 and C-03-32 
patients were randomized to receive nepafenac 0.1% at differ-
ent dosing schedules, 1 drop daily, twice daily, 3 times a day, 
or placebo given with the above dosing regimen. All of the 
studies (except C-95-91) used aqueous cells and ﬂ  are (signs 
of inﬂ  ammation) as basis for evaluating the efﬁ  cacy of the 
drug product. Using slit-lamp biomicroscopy is a standard 
practice in ophthalmology to evaluate inﬂ  ammation, using 
aqueous cells and ﬂ  are; the lower the score the lower the 
inﬂ  ammation. The results of study C-02-53 demonstrated 
that 3-times-a-day regimen proved to be more efﬁ  cacious 
than nepafenac given daily or twice daily, based upon the 
percentage of treatment failures (3 times a day 19.6% vs 
daily 25% vs twice daily 30%).
As one would expect, nepafenac was superior to placebo 
in all three dose regimens. Both studies achieved statistical 
signiﬁ  cance in terms of efﬁ  cacy with more patients receiv-
ing nepafenac vs placebo pain free on days 1, 3, 7, and 14 
(National PBM drug monograph 2006). In a randomized 
double-blinded study of 476 patients evaluating safety and 
effectiveness of nepafenac in preventing and treating post-
cataract surgery inﬂ  ammation and pain, a higher percent-
age of patients in the nepafenac group were pain-free at all 
visits (83.1%–93%) compared with vehicle-treated patients 
(41.6%–46.4%) (p   0.0001) (Lane et al 2007). While these 
studies ﬁ  rmly demonstrate the efﬁ  cacy of nepafenac against 
a placebo, comparative drug – drug studies with other topical 
NSAIDs are less conclusive.
Notably, individual study of the effect of ketorolac on 
moderate to severe ocular inﬂ  ammation after cataract surgery 
noted equivocal response in controlling pain (p = 0.049) 
(Heier et al 1999). In contrast, studies with nepafenac showed 
a signiﬁ  cant effect in reducing pain following cataract surgery 
(p   0.001) (Lane et al 2007). However, the study population 
examined by Lane differed signiﬁ  cantly from the ketorolac 
population in that subjects did not demonstrate moderate to 
severe inﬂ  ammation as noted in the ketorolac study, and were 
consecutively enrolled into the study simply because of the 
need for cataract surgery not because they demonstrated any 
particular level of discomfort. Additional reports have sug-
gested that comparative studies between nepafenac and corti-
costeroids and other NSAIDs would be desirable (Colin and 
Paquette 2006).  A study, however, by Nardi et al examined 
differences between ketorolac 0.5%, nepafenac 0.1%, and pla-
cebo for control of pain and inﬂ  ammation following cataract 
extraction and posterior chamber lens implantation (Nardi 
et al 2007). Although ﬁ  ndings by Nardi et al demonstrate a 
higher “cure rate” deﬁ  ned by a total absence of cell and ﬂ  are 
on day 14 for the nepafenac product, by day 21 ketorolac 
slightly exceeded that of nepafenac in terms of cure rate. 
Moreover, despite manufacturer recommendations of 4 times-
a-day day dosing for control of post-operative inﬂ  ammation, 
ketorolac was dosed at a 3 times-a-day interval in the Nardi 
et al study which may have biased results toward nepafenac. 
It is noteworthy that subjects who received placebo 
demonstrated a dramatic improvement in anterior segment 
inﬂ  ammation described by the presence of cell and ﬂ  are from 
day 7 to 21 thus suggesting the confounding effect of normal 
healing on overall comparative product effectiveness. 
Safety of ophthalmic NSAIDs 
with a discussion of nepafenac
Topical ophthalmic NSAIDs have become increasingly popu-
lar among cataract surgeons due to the fact that treatment can 
be initiated pre-operatively and continued post-operatively 
to provide not only better anti-inﬂ  ammatory control with 
analgesia, but, as an added beneﬁ  t, maintenance of intra-
operative pupil dilation. Because of these favorable ﬁ  ndings, 
the NSAID market has been growing through wider use not 
only in cataract surgery, but as an anti-inﬂ  ammatory adjunct 
in procedures such as refractive and various types of retinal 
surgery as well. Although topical ophthalmic NSAIDs are in 
general considered safe and effective therapeutic entities when 
used in an appropriate manner, they are not without detriment 
and have been linked to various forms of corneal toxicity that 
in some cases have been particularly severe. As an example, 
diclofenac sodium ophthalmic solution (DSOS), previously 
manufactured by Falcon Pharmaceuticals, was associated with 
a cluster of corneal events deﬁ  ned by the presence of severe 
corneal melts that eventually led to removal of the Falcon 
product from the marketplace. Corneal melt associated with Clinical Ophthalmology 2008:2(2) 364
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the other formulations of ophthalmic diclofenac have been 
reported as well (Voltaren®, Novartis Ophthalmics, East 
Hanover, NJ) (Gaynes and Fiscella 2002).
Adverse events characterized by severe corneal melts 
associated with the Falcon DSOS product were considered 
to be most likely related to the presence of the vitamin E 
based solubilizer tocophersolan found in the DSOS product 
(Gaynes and Fiscella 2002). Curiously, the occurrence of 
corneal inﬁ  ltrates concomitantly with use of oral diclofenac 
has also been reported and is thought to be related to the 
increased production of lipoxygenase-derived LTB4, a poly-
morphonuclear chemotactic (Tabbara 2000). Of further inter-
est, topical ophthalmic diclofenac has been found to decrease 
levels of substance P in human tears (Yamada et al 2002). 
Depletion of neuropeptides such as substance P within the 
corneal epithelium has been associated with delayed wound 
healing and may induce conditions conducive to the develop-
ment of neurotrophic keratopathy (Yamada et al 2002). The 
association, however, of substance P depletion with other 
ophthalmic NSAIDs remains to be fully elucidated.
After removal of the Falcon DSOS from commercial 
use, the incidence of severe corneal events associated with 
NSAID use reported to the US FDA dropped precipitously. 
However, since removal of Falcon DSOS from the market 
in September 1999, scattered reports noting the association 
between severe corneal injury and use of topical NSAIDs 
have persisted, albeit not at the rate associated with the Falcon 
product. Ketorolac and bromfenac have both been associated 
with severe corneal injury; however, the circumstances of 
their use in these events is questionable (Asai et al 2006; 
Mian et al 2006). A report describing the occurrence of cor-
neal melt with perforation occurring with topical bromfenac 
use also has been documented (Isawi and Dhaliwal 2007). 
Furthermore, a report has also been noted demonstrating the 
occurrence of a corneal melt associated with use of nepaf-
enac (Wolf et al 2007). The latter circumstance involved a 
56-year-old woman with graft-vs host disease who experi-
enced a central corneal perforation after use of nepafenac 
after cataract surgery (Wolf et al 2007).
Commercially available nepafenac ophthalmic suspen-
sion is marketed in the US under the name Nevanac® and 
is combined with various inactive components to maintain 
pH, tonicity, and sterility, including mannitol, sterile water, 
sodium chloride, edetate disodium, benzalkonium chloride, 
sodium hydroxide, and/or hydrochloric acid as well as car-
bomer 974P and tyloxapol. Carbomer 974 is a non-detergent 
water-based buffering agent that is a highly negatively charged 
high-molecular-weight polymer that provides thousands of 
active, ionizable carboxyl groups for acid buffering activity 
(AIDS Info). Clinical trials of Carbomer 974 as a buffering 
agent to maintain vaginal acidity in HIV studies demonstrated 
erythema and pruritis as the most common side effects associ-
ated with its use (AIDS Info). Tyloxapol is a detergent-based 
non-ionic liquid polymer of the alkyl aryl polyether alcohol 
type used as a surfactant to aid liquefaction (Tyloxapol). At 
concentrations of 0.2%–1.0% tyloxapol has been shown to 
induce concentration-dependent structural changes in high 
density lipoproteins (Yamamoto et al 1984). Tyloxapol also 
has been shown to inhibit lipoprotein lipase; however the 
long-term toxicologic effects of tyloxapol on the cornea at 
the concentration used in nepafenac ophthalmic solution is 
unknown (Bhatia and Wade 1991).
Corneal toxicity can be an issue with NSAID use and 
as such typically involves problems ranging from corneal 
stinging to punctuate keratopathy and persistent epithelial 
erosion. Nepafenac 0.1% ophthalmic suspension has the 
potential, as do all topical NSAIDs, to slow or delay healing 
and to cause keratitis (Gaynes and Fiscella 2002). Patients 
with complicated ocular conditions (eg, corneal denervation, 
corneal epithelial defects, diabetes mellitus, rheumatoid 
arthritis, and repeat and/or complex ocular surgeries) may be 
at an increased risk of corneal adverse events due to topical 
NSAID use (Gaynes and Fiscella 2002). Topical NSAIDS 
(including nepafenac) used concurrently with topical cor-
ticosteroids may increase the potential for slow or delayed 
healing. Therefore, the combined use of corticosteroids and 
topical NSAIDs may result in keratitis in susceptible patients, 
with prolonged use ( 4 weeks) resulting in epithelial break-
down, corneal thinning, corneal erosion, corneal ulceration 
or corneal perforation (Gaynes and Fiscella 2002; Nevanac®). 
It should be pointed out, however, that NSAIDs-related cor-
neal toxicity often occurs inconsistently with variable dose 
relationships, thereby suggesting etiologies perhaps more 
related to susceptibility rather than frank chemical toxicity 
as the deﬁ  ning cause of corneal injury (Flach 2001).
In addition to local toxicity, isolated reports of systemic 
toxicity have been associated with use of topical NSAIDs 
(Estes et al 1993; Chan 1995; Sharir 1997). Reports of 
asthma exacerbation, gastrointestinal erosions, and bleed-
ing have been associated with use of systemic as well as 
topical ophthalmic NSAIDs (Estes et al 1993; Chan 1995; 
Sharir 1997). According to studies in rabbits, 74% of the 
administered topical ophthalmic dose of ketorolac reaches the 
systemic circulation through nasolacrimal drainage (Ling and 
Combs 1987). It is unclear, however, if similar ﬁ  ndings are 
duplicated in humans. Nepafenac is not an inhibitor of the in Clinical Ophthalmology 2008:2(2) 365
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vitro metabolism of the major cytochrome (CYP) isozymes 
(CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and 
CYP3A4) at therapeutic concentrations used in ophthalmic 
indications (Nevanac®). Therefore, interactions involving 
concurrently used systemic drugs that are metabolized by 
CYP are unlikely. Drug interactions with nepafenac mediated 
by protein binding are also unlikely according to the opinion 
of the manufacturer (Nevanac®). Concurrent use of nepafenac 
with medications that prolong bleeding time may increase 
the risk of hemorrhage due to interference by nepafenac 
with thrombocyte aggregation. Moreover, there have been 
reports that ophthalmic non-steroidal anti-inﬂ  ammatory 
drugs may increase bleeding in ocular tissues (including 
hyphema) in conjunction with ocular surgery (Gaynes and 
Fiscella 2002). One must be particularly cautious in initiating 
topical NSAID use particularly for long-term usage in the 
presence of concomitant risk factors such as with those 
who use concurrent systemic NSAIDs, use tobacco and/or 
alcohol, and/or are included in geriatric, pediatric, or other 
vulnerable populations.
Nepafenac warning labels indicate there is cross-sensitivity 
to acetylsalicylic acid, phenylacetic acid derivatives, and 
other non-steroidal anti-inﬂ  ammatory agents (Nevanac®). 
Therefore caution should be used when treating individuals 
who have previously exhibited sensitivity to these drugs. As 
a rule the inhibition of COX2 determines the clinical efﬁ  cacy 
of a topical NSAID. In systemic use NSAID selectivity for 
one COX isoform has been shown to affect clinical safety. 
Drugs with more selectivity for COX2 than COX1 tend to 
have fewer gastrointestinal side effects but have been associ-
ated with increased risk for hepatotoxicity, edema, hyperten-
sion, and cardiovascular problems. Although uncommon, 
the occurrence of systemic adverse events related to topical 
ophthalmic NSAIDS should not be discounted (Jampol et al 
1994; Malhotra et al 2004; Warner et al 2004).
The most frequent adverse events reported in clinical 
trials with nepafenac to date have been ocular in nature; 
however, the deﬁ  nitive causality is obscure. Approximately 
5%–10% of the patients demonstrated post-operative cap-
sular opacity, decreased visual acuity, foreign body sensa-
tion, increased intraocular pressure, and a sticky sensation 
(Nevanac®). Fewer frequent ocular adverse events (1%–5%) 
included conjunctival edema, corneal edema, dry eye, lid 
margin crusting, ocular discomfort, ocular hyperemia, ocu-
lar pain, ocular pruritis, photophobia, tearing, and vitreous 
detachment. Non-ocular adverse (1%–4%) events included 
hypertension, headache, nausea/vomiting, and sinusitis 
(Nevanac®). Concentrations of this drug have been evaluated 
at 15 times the commercial marketed dose without any 
signiﬁ  cant complications in animal studies (McGee et al 
2005; Walker et al 2005).
In the randomized vehicle-controlled clinical trial by Lane 
and colleagues evaluating nepafenac for treatment of pain 
and inﬂ  ammation after cataract surgery, no ocular adverse 
events of deﬁ  nitive relationship to nepafenac therapy were 
reported (Lane et al 2007). Ocular adverse events reported 
by Lane et al occurring at an incidence of 1% or greater 
included decreased visual acuity, photophobia, capsule 
opacity, foreign body sensation, ocular hyperemia, ocular 
pruritis, ocular discomfort, dry eye, increased intraocular 
pressure, and blurred vision (Lane et al 2007). None of the 
events were considered serious and in large part of mild 
intensity and resolved without complication. These events 
occurred with similar incidence in both nepafenac 0.1% and 
the vehicle group. The incidence of ocular adverse events 
such as decreased visual acuity rates and capsular opacity 
were indeed similar in patients receiving nepafenac 0.1% 
and those receiving vehicle (3.2% vs 3.8% and 2.0% vs 2.5% 
respectively (Lane et al 2007).
The use of NSAIDs after refractive surgery for control of 
pain and inﬂ  ammation is a growing indication for this class 
of drug. In addition to typical LASIK procedures, refrac-
tive surgery also involves surface ablation photorefractive 
keratectomy such as laser-assisted sub-epithelial keratec-
tomy (LASEK) and epi-LASEK. After surface ablation 
procedures, a contact lens is placed in the eye to promote 
epithelial regeneration. In one randomized double masked 
study of ketorolac 0.4% vs nepafenac 0.1% for control of pain 
after surface ablation, eyes treated with nepafenac tended to 
demonstrate greater corneal haze as well as slower epithelial 
healing compared with ketorolac, resulting in discontinuation 
of the study due to safety concerns (Trattler et al 2005). It 
appears that use of nepafenac after surface ablation greatly 
augments the risk of corneal toxicity, notably corneal haze 
and delayed healing, particularly if used for longer than a 
3-day post-operative interval (Durrie et al 2006; Reilly and 
Cadwell 2006; William Trattler pers comm March 3, 2008). 
The rationale for nepafanac-related corneal injury follow-
ing PRK is unclear as bioactivation of nepafenac within the 
cornea is reported to be very low (Colin and Paquette 2006). 
Persistent corneal haze after use of nepafenac after surface 
ablation procedures may, although unlikely, be related to 
direct chemical toxicity of the prodrug entity rather than a 
consequence of the pharmacodynamic actions of amfenac. 
More compelling is the notion of water-based hydrolysis of 
nepafenac within the matrix of the hydrophilic soft contact Clinical Ophthalmology 2008:2(2) 366
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lens leading to nepafenac bioactivation. With repeated dosing, 
nepafenac may be adsorbed and accumulate within silicon 
hydrophilic bandage lenses which provide a substrate for 
water-based amide hydrolysis resulting in a steady source 
of amfenac leaching from the lens matrix.
It should be noted, however, that analysis of nepafenac 
in terms of corneal healing and analgesia following PRK as 
studied by Caldwell and Reily found that while analgesia was 
signiﬁ  cantly enhanced in the nepafenac group, a concomitant 
delay in corneal wound healing was not evident. Corneal 
injury following PRK was indeed fully healed equally in both 
the nepafenac and placebo groups by post-operative day 5 
(Caldwell and Reilly 2008). Further analysis by Donnefeld et 
al found that neither nepafenac nor ketorolac reduced corneal 
healing time following PRK and both drugs demonstrated 
a beneﬁ  cial effect in terms of analgesia (Donnenfeld et al 
2007). Colin and Paquette described corneal epithelial healing 
rate with use of 0.03% or 0.1% nepafenac or 0.1% diclof-
enac. Furthermore, Colin and Paquette found no difference 
in corneal epithelial healing rate among the three study 
formulations; however, a small corneal inﬁ  ltrate was noted in 
the 0.03% nepafenac group that was deemed possibly related 
to the study medication (Colin and Paquette 2006). It should 
be noted, however, that in all studies mentioned describing 
PRK and corneal epithelial healing rate with various topical 
NSAIDs, subjects were followed for a maximum of 5–7 days 
with no comment on the appearance of the cornea following 
re-epithelization. Interestingly, corneal haze following PRK 
can occur weeks, months, or even years following PRK and 
is related to abnormalities in healing of the corneal stroma 
rather than epithelium (Majmudar et al 2000).
As a corollary to issues pertaining to refractive surgery, it 
is interesting to note that nepafenac is considered to demon-
strate greater corneal analgesic effect compared with drugs 
such as diclofenac or ketorolac (Acosta et al 2007). This ﬁ  nd-
ing is largely due to the ability of nepafenac to partition into 
corneal epithelium quickly and efﬁ  ciently compared more 
polar analogs. It has also been shown that unlike diclofenac, 
nepafenac does not exhibit local anesthetic qualities (Acosta 
et al 2007).
Reproduction studies performed with nepafenac in 
rabbits and rats at oral doses up to 10 mg/kg/day have 
revealed no evidence of teratogenicity due nepafenac, 
despite induction of maternal toxicity (Nevanac®). At this 
dose, the animal plasma exposure of nepafanac and amf-
enac was 80 and 680 times human plasma exposure for 
rabbits, respectively, when nepafanac was used at manu-
facturer recommended ophthalmic doses. In rats maternal 
toxic doses  10 mg/kg were associated with increased 
post-implantation loss, reduced fetal weights and growth, 
and reduced fetal survival. There have been no adequate, 
well-controlled trials for the use of nepafenac in pregnant 
women; therefore, its use should be avoided in the late 
stages of pregnancy (third trimester) due to the known 
effects of prostaglandin biosynthesis inhibition on the fetal 
cardiovascular system (closure of the ductus arteriosus). 
Nepafenac is considered pregnancy category C (Nevanac®). 
Nepafenac has been shown to cross placental barrier in 
rats. Because animal reproduction studies are not always 
predictive of human response, nepafenac should be used 
during pregnancy only if the potential beneﬁ  t justiﬁ  es the 
potential risk to the fetus (Nevanac®).
Nepafenac should be used with caution in nursing moth-
ers. Nepafenac was excreted in the milk of pregnant rats. 
Because it is not known whether this drug is excreted in 
human milk, caution should be exercised when nepafenac is 
administered to a nursing woman (Nevanac®).
Nepafenac has not been evaluated in long-term carcino-
genicity studies. Increased chromosomal aberrations were 
observed in Chinese hamster ovary cells exposed in vitro 
to nepafenac suspension. Nepafenac did not impair fertility 
when administered orally to male and female rats at 3 mg/kg 
(approximately 90 and 380 times the plasma exposure to 
the parent drug, nepafenac, and active metabolite, amfenac, 
respectively, at the recommended human topical ophthalmic 
dose) (Nevanac®).
Nepafenac dosage and 
administration for ocular use
The approved FDA labeling for nepafenac states that 1 drop 
of nepafenac is to be applied to the affected eye(s) 3 times 
a day. Therapy begins 1 day prior to cataract surgery and 
continues the day of surgery and through the ﬁ  rst 2 weeks 
of the post-operative period. The use of nepafenac beyond 
the recommended therapeutic time frame may increase 
the risk of adverse corneal events as noted in the FDA-
approved drug labeling (Nevanac®). Safety of nepafenac 
has not been determined in pediatric patients below the age 
10 years (Nevanac®). Each milliliter of nepafenac suspension 
contains 1 mg of nepafenac and should be shaken well prior 
to instillation.
Topical ophthalmic NSAIDs such as ketorolac have been 
administered without incident in combination with other topi-
cal ophthalmic products including antibiotics, beta blockers, 
carbonic anhydrase inhibitors, cycloplegics, and mydriat-
ics (Acular® 2003). Nepafenac would also be expected to Clinical Ophthalmology 2008:2(2) 367
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be safely administered in combination with other topical 
ophthalmic products; however, dosage should be spaced 
at least in 5-minute intervals to prevent drug washout and 
dilution and to maximize drug absorption. The concomitant 
use of topical NSAIDs, however, in conjunction with topical 
and/or enteral corticosteroids must be carefully monitored, 
particularly among patients at high risk for corneal injury 
such as those with rheumatoid arthritis or fulminate collagen 
vascular disorders (Gaynes and Fiscella 2002).
Conclusion
Nepafenac is the first prodrug ophthalmic NSAID for-
mulation approved for use in the US for the treatment of 
post-operative pain and inﬂ  ammation after cataract surgery. 
Nepafenac itself has little activity on COX enzyme activity 
and requires deamination to the more active congener amf-
enac for therapeutic action. Although amfenac demonstrates 
marked COX inhibitory potential, differences in NSAID 
potency as described in comparative reviews of COX IC50 
activity should not be the sole determinant of effective oph-
thalmic NSAID utilization clinically.
The theoretical advantage offered by nepafenac over 
other existing NSAIDs is in corneal penetration. However, 
the expected therapeutic advantage of nepafenac based 
on its corneal permeability proﬁ  le and absorption is not 
fully recognizable in comparative assessment of clinical 
anti-inﬂ  ammatory efﬁ  cacy. The issue of bioactivation as it 
pertains to nepafenac is a key point in pharmacodynamics 
pertaining to the active amfenac entity. Although nepafenac 
is metabolized in the mammalian iris and retina, the rate of 
amide hydrolysis demonstrable in human aqueous has not 
been fully elucidated; therefore, comparative prediction 
regarding peak nepafenac concentration in aqueous as an 
implied indicator of effectiveness in the human is at best 
equivocal.
All commercially available topical ophthalmic NSAIDs 
are effective inhibitors of COX activity; whether or not one 
drug has greater or lower IC50 value is therefore not directly 
correlated with clinical indicators of therapeutic effectiveness. 
In the case of topical ophthalmic NSAIDs, practitioners should 
carefully weigh the cost-beneﬁ  t of implementing “highly 
potent” new drug products because perturbations in pharma-
codynamic response due to the inherent novelty in terms of 
chemical designs may outweigh the demonstrated replicative 
pharmacologic action of all topical ophthalmic NSAIDs.
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